| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2005PNAS..102.3378T |
| P356 | DOI | 10.1073/PNAS.0409899102 |
| P932 | PMC publication ID | 549291 |
| P698 | PubMed publication ID | 15728371 |
| P5875 | ResearchGate publication ID | 8006029 |
| P50 | author | Hugh S Mason | Q52655688 |
| P2093 | author name string | Yasmin Thanavala | |
| Charles J Arntzen | |||
| Martin Mahoney | |||
| Nachimuthu Natarajan | |||
| Adrienne Scott | |||
| Liz Richter | |||
| Patti Goodwin | |||
| Sribani Pal | |||
| P2860 | cites work | Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994 | Q64132287 |
| Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine | Q64378212 | ||
| Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine | Q69980590 | ||
| Global programme for control of hepatitis B infection | Q71772495 | ||
| Hepatitis B vaccination: how long does protection last? | Q72586604 | ||
| Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy | Q72820566 | ||
| Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn | Q80842328 | ||
| Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group | Q28241816 | ||
| Oral immunization with hepatitis B surface antigen expressed in transgenic plants | Q33944696 | ||
| Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene | Q34067072 | ||
| Immunogenicity of transgenic plant-derived hepatitis B surface antigen | Q34437147 | ||
| Expression of hepatitis B surface antigen in transgenic plants | Q37337644 | ||
| Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice | Q37584470 | ||
| Serologic hepatitis B immunity in vaccinated health care workers | Q39512286 | ||
| Novel hepatitis B vaccines | Q40827817 | ||
| Vaccine visions and their global impact | Q40859544 | ||
| Structural characterization of plant-derived hepatitis B surface antigen employed in oral immunization studies | Q44551914 | ||
| Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes | Q45741675 | ||
| Incidence of Hepatitis B Virus Infection in the United States, 1976–1994: Estimates from the National Health and Nutrition Examination Surveys | Q45752990 | ||
| Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato | Q47614578 | ||
| Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders | Q50957034 | ||
| Oral immunization with a recombinant bacterial antigen produced in transgenic plants | Q54612499 | ||
| Production of hepatitis B surface antigen in transgenic plants for oral immunization | Q57235165 | ||
| PUBLIC HEALTH:Reducing Liver Cancer--Global Control of Aflatoxin | Q58296818 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | edibility | Q123989417 |
| vaccine | Q134808 | ||
| P304 | page(s) | 3378-3382 | |
| P577 | publication date | 2005-02-22 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Immunogenicity in humans of an edible vaccine for hepatitis B. | |
| P478 | volume | 102 |
| Q42200961 | A DNA replicon system for rapid high-level production of virus-like particles in plants |
| Q59335426 | A Preliminary Study of a Lettuce-Based Edible Vaccine Expressing the Cysteine Proteinase of for Fasciolosis Control in Livestock |
| Q36252789 | A launch vector for the production of vaccine antigens in plants |
| Q64068510 | Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines |
| Q38356275 | An overview of tuberculosis plant-derived vaccines |
| Q50993380 | Analysis of the limitations of hepatitis B surface antigen expression in soybean cell suspension cultures |
| Q36991555 | Antiviral potentials of medicinal plants |
| Q36436921 | Assessing commercial feasibility: a practical and ethical prerequisite for human clinical testing |
| Q40372084 | Biochemical and biophysical characterization of maize-derived HBsAg for the development of an oral vaccine |
| Q41869849 | Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen |
| Q51052832 | Booster responses by oral vaccination with transgenic plants against chicken leucocytozoonosis |
| Q39106728 | Cholera toxin B protein in transgenic tomato fruit induces systemic immune response in mice |
| Q37324787 | Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes |
| Q26783099 | Commercial-scale biotherapeutics manufacturing facility for plant-made pharmaceuticals |
| Q36640326 | Delivery systems and adjuvants for oral vaccines. |
| Q92259179 | Development of Systems for the Production of Plant-Derived Biopharmaceuticals |
| Q38099730 | Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures |
| Q37776721 | Development of plant-based mucosal vaccines against widespread infectious diseases. |
| Q51152189 | Ethics, biotechnology, and global health: the development of vaccines in transgenic plants |
| Q33345905 | Expression of HIV-1 antigens in plants as potential subunit vaccines |
| Q54385790 | Expression of avian reovirus minor capsid protein in plants |
| Q54432136 | Expression of toxin co-regulated pilus subunit A (TCPA) of Vibrio cholerae and its immunogenic epitopes fused to cholera toxin B subunit in transgenic tomato (Solanum lycopersicum). |
| Q26782486 | Farming of Plant-Based Veterinary Vaccines and Their Applications for Disease Prevention in Animals |
| Q38104626 | Hairy Roots as a Vaccine Production and Delivery System |
| Q24241852 | Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status |
| Q35531633 | Hepatocytes Traffic and Export Hepatitis B Virus Basolaterally by Polarity-Dependent Mechanisms |
| Q38992414 | Heterologous protein production in plant systems |
| Q51808636 | Human CD14 expressed in seeds of transgenic tobacco displays similar proteolytic resistance and bioactivity with its mammalian-produced counterpart |
| Q46308392 | Immunization without needles |
| Q45399996 | Immunogenicity of recombinant hepatitis B virus surface antigen fused with preS1 epitopes expressed in rice seeds |
| Q35960908 | Immunological Characterization of Plant-Based HIV-1 Gag/Dgp41 Virus-Like Particles |
| Q36837152 | Implication of nanoparticles/microparticles in mucosal vaccine delivery |
| Q30350670 | Is there a role for plant-made vaccines in the prevention of HIV/AIDS? |
| Q42727635 | Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation |
| Q35598223 | Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus |
| Q82345610 | Mucosal immunization using recombinant plant-based oral vaccines |
| Q36945838 | Needle-free vaccine delivery |
| Q51377774 | New Strategies Toward Edible Vaccines: An Overview |
| Q30886978 | Next biotech plants: new traits, crops, developers and technologies for addressing global challenges |
| Q38229883 | Novel transgenic rice-based vaccines |
| Q84749619 | Obtaining tomato plants transgenic for the preS2-S-HDEL gene, which synthesize the major hepatitis B surface antigen |
| Q84089776 | Oral administration of low doses of plant-based HBsAg induced antigen-specific IgAs and IgGs in mice, without increasing levels of regulatory T cells |
| Q42231366 | Oral delivery of plant-derived HIV-1 p24 antigen in low doses shows a superior priming effect in mice compared to high doses |
| Q35653717 | Oral delivery of wafers made from HBsAg-expressing maize germ induces long-term immunological systemic and mucosal responses. |
| Q36118497 | Oral hepatitis B vaccine candidates produced and delivered in plant material |
| Q44236375 | Oral immunization of mice with lily pollen expressing HBsAg |
| Q80197599 | Oral immunogenicity of potato-derived HBsAg middle protein in BALB/c mice |
| Q37597955 | Oral transgenic plant-based vaccine for hepatitis B. |
| Q51037305 | Oral vaccination of mice with Tremella fuciformis yeast-like conidium cells expressing HBsAg |
| Q37229915 | Oral vaccine delivery: can it protect against non-mucosal pathogens? |
| Q35915872 | Oral vaccines: A spoonful of antigen |
| Q37789954 | Overview of expression of hepatitis B surface antigen in transgenic plants |
| Q26782569 | Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants |
| Q41041066 | Plant expression, lyophilisation and storage of HBV medium and large surface antigens for a prototype oral vaccine formulation |
| Q92581227 | Plant factory: new resource for the productivity and diversity of human and veterinary vaccines |
| Q51211891 | Plant foods for human health: research challenges |
| Q91346436 | Plant lyophilisate carrying S-HBsAg as an oral booster vaccine against HBV |
| Q37776722 | Plant-based vaccines against human hepatitis B virus |
| Q38823962 | Plant-based vaccines against respiratory diseases: current status and future prospects |
| Q34687464 | Plant-based vaccines against viruses. |
| Q26775788 | Plant-based vaccines for animals and humans: recent advances in technology and clinical trials |
| Q37910821 | Plant-derived antigens as mucosal vaccines |
| Q41439514 | Plant-derived recombinant F1, V, and F1-V fusion antigens of Yersinia pestis activate human cells of the innate and adaptive immune system |
| Q36445550 | Plant-derived vaccines: a look back at the highlights and a view to the challenges on the road ahead |
| Q36888029 | Plant-derived virus-like particles as vaccines |
| Q37776713 | Plant-made immunogens and effective delivery strategies |
| Q26783111 | Plant-made oral vaccines against human infectious diseases-Are we there yet? |
| Q37859060 | Plant-made pharmaceuticals: leading products and production platforms. |
| Q37616370 | Plant-made vaccine antigens and biopharmaceuticals |
| Q30386732 | Plant-made vaccines for humans and animals. |
| Q36439033 | Plant-made vaccines: biotechnology and immunology in animal health |
| Q26775069 | Plants as Factories for Human Pharmaceuticals: Applications and Challenges |
| Q37438883 | Plants as bioreactors for the production of vaccine antigens. |
| Q38121856 | Plant‐derived pharmaceuticals for the developing world |
| Q56853265 | Potatoes pack a punch against hepatitis B |
| Q36755687 | Production of hepatitis B surface antigen in recombinant plant systems: an update |
| Q42012175 | Production of highly concentrated, heat-stable hepatitis B surface antigen in maize |
| Q36655994 | Production of pharmaceutical proteins in solanaceae food crops |
| Q37810816 | Progress towards a needle-free hepatitis B vaccine |
| Q34250117 | Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system |
| Q36505675 | Protein glycosylation in diverse cell systems: implications for modification and analysis of recombinant proteins |
| Q38864181 | Recombinant biologic products versus nutraceuticals from plants - a regulatory choice? |
| Q39571255 | Recombinant protein yield in rice seed is enhanced by specific suppression of endogenous seed proteins at the same deposit site |
| Q40051873 | Reconceptualizing cancer immunotherapy based on plant production systems |
| Q36238737 | Regulatory issues for plant-made pharmaceuticals and vaccines |
| Q40384072 | Risk analysis for plant-made vaccines |
| Q37940792 | Role of transgenic plants in agriculture and biopharming |
| Q38966684 | Supercritical fluid extraction provides an enhancement to the immune response for orally-delivered hepatitis B surface antigen |
| Q28073401 | The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B |
| Q26744351 | The Potential for Microalgae as Bioreactors to Produce Pharmaceuticals |
| Q36590168 | The Twenty-Year Story of a Plant-Based Vaccine Against Hepatitis B: Stagnation or Promising Prospects? |
| Q38278302 | The mucosal immune system for vaccine development |
| Q26783887 | The mucosal immune system: From dentistry to vaccine development |
| Q58917333 | Therapeutic effectiveness of orally administered transgenic low-alkaloid tobacco expressing human interleukin-10 in a mouse model of colitis |
| Q37744913 | Transgenic plant-based oral vaccines |
| Q90669923 | Transgenic plants for animal health: plant-made vaccine antigens for animal infectious disease control |
| Q57261183 | Use of Plant Viruses for Production of Plant-Derived Vaccines |
| Q33870122 | Vaccination via Chloroplast Genetics: Affordable Protein Drugs for the Prevention and Treatment of Inherited or Infectious Human Diseases |
| Q57235149 | Vaccine Production: Plants as Biofactories |
| Q44862237 | Vaccine manufacturing: challenges and solutions |
| Q34617331 | Viral nanoparticles as macromolecular devices for new therapeutic and pharmaceutical approaches |
| Q37106374 | Viral vectors for production of recombinant proteins in plants |
| Q38059059 | Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development |
| Q38081975 | Virus-like particles produced in plants as potential vaccines |
| Q24650772 | Virus-like particles production in green plants |
| Q83971058 | WHO informal consultation on scientific basis for regulatory evaluation of candidate human vaccines from plants, Geneva, Switzerland, 24-25 January 2005 |
Search more.